PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO

PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO

SUMMARY

The IPO will consist solely of freshly issued shares as no existing investor is selling shares

The company plans to use the IPO proceeds to repay outstanding borrowings, support working capital, and invest in its subsidiary, Buildmex-Infra Pvt Ltd

Founded in February 2021 by Ronak Morbia and Bhavik Khara, ArisInfra uses AI and machine learning to simplify construction material procurement

Technology-driven construction material procurement platform ArisInfra Solutions has filed its draft red herring prospectus (DRHP) with the markets regulator Securities and Exchange Board of India (SEBI) to raise INR 600 Cr via an initial public offering (IPO). 

The IPO will consist solely of freshly issued shares as no existing investor is selling shares.

ArisInfra counts a host of wealthy individuals and family offices, including PharmEasy chief executive Siddharth Shah, San Francisco-based Think Investments, and partners from private equity firms such as TPG Capital and BlackRock among its backers.

The company plans to use the IPO proceeds to repay outstanding borrowings, support working capital, and invest in its subsidiary, Buildmex-Infra Pvt Ltd. The funds will also be used to buy partial shareholdings from existing shareholders of ArisUnitern Re Solutions and for general corporate purposes and potential acquisitions.

Founded in February 2021 by Ronak Morbia and Bhavik Khara, ArisInfra uses AI and machine learning to simplify construction material procurement. The platform links property developers with vendors, digitising the construction industry’s supply chain.

It is a new age material procurement and smart financing platform for infrastructure and construction companies.

According to the report, the company has raised INR 160 Cr in equity and an equivalent amount in debt. Its latest funding round in January 2022 valued the company at approximately $100 Mn.

Its clients include Tata Group, JSW, UltraTech Cement, ACC, Dalmia, Godrej, Larsen & Toubro, Apco Infra, SP Singla Constructions, and Lafarge.

For fiscal 2024, the company reported revenue of INR 700 Cr and EBITDA of INR 40 Cr. It has remained profitable since its inception.

JM Financial, IIFL Securities, and Nuvama Wealth Management are the lead managers for the proposed issue.

This move coincides with increased investor interest in proptech startups, which are seen as key players in digitally transforming the real estate market.

For instance, a few days back, Mumbai-based Truva raised $3 Mn in a seed funding round led by Stellaris Venture Capital, along with participation from Peercheque and a host of angel investors.

In July, Private equity firm HDFC Capital picked up 8.5% stake in Mumbai-based proptech startup TruBoard for an undisclosed amount.

Note: We at Inc42 take our ethics very seriously. More information about it can be found here.

You have reached your limit of free stories
Become An Inc42 Plus Member

Become a Startup Insider in 2024 with Inc42 Plus. Join our exclusive community of 10,000+ founders, investors & operators and stay ahead in India’s startup & business economy.

2 YEAR PLAN
₹19999
₹7999
₹333/Month
Unlock 60% OFF
Cancel Anytime
1 YEAR PLAN
₹9999
₹4999
₹416/Month
Unlock 50% OFF
Cancel Anytime
Already A Member?
Discover Startups & Business Models

Unleash your potential by exploring unlimited articles, trackers, and playbooks. Identify the hottest startup deals, supercharge your innovation projects, and stay updated with expert curation.

PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO-Inc42 Media
How-To’s on Starting & Scaling Up

Empower yourself with comprehensive playbooks, expert analysis, and invaluable insights. Learn to validate ideas, acquire customers, secure funding, and navigate the journey to startup success.

PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO-Inc42 Media
Identify Trends & New Markets

Access 75+ in-depth reports on frontier industries. Gain exclusive market intelligence, understand market landscapes, and decode emerging trends to make informed decisions.

PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO-Inc42 Media
Track & Decode the Investment Landscape

Stay ahead with startup and funding trackers. Analyse investment strategies, profile successful investors, and keep track of upcoming funds, accelerators, and more.

PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO-Inc42 Media
PharmEasy CEO-Backed ArisInfra Files Draft Papers For INR 600 Cr IPO-Inc42 Media
You’re in Good company